PharmaMar will present final data on PM1183 during the 18th World Lung Conference in Japan

(Pharmamar) PharmaMar (MSE:PHM) will present the final efficacy and safety data obtained from the Phase I/II trial combining PM1183 (lurbinectedin).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news